Kymab Limited

F-star Therapeutics, Inc.

Invox Pharma Limited

Frederick Akele

Mihriban Tuna

Francisca Wollerton Van Horck

Mustapha Faroudi

Ryan Fiehler

Fadi Badr

Jamie Iain Campbell

Matthew John McCourt

Richard Charles Alfred Sainson

Stephen John Arkinstall

Cyril Privezentzev

Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.

Bispecific antibody for ICOS and PD-L1

The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.

FC binding fragments comprising a PD-L1 antigen-binding site

Growing community of inventors

Cambridge, United Kingdom

Frederick Akele